July 9, 2008
Investment Value of Top 10 North American Life Science Projects Drops 34% to $2.9 Billion in 2008, an Industrial Info News Alert
Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas) -- An analysis of the top 10 North American Pharmaceutical & Biotech capital projects currently scheduled to begin construction in 2008 reveals a cumulative total investment value (TIV) of $2.9 billion. Although the figure is impressive, it is a 34% drop compared with the same analysis of last year's top 10 projects, which totaled $4.4 billion. Shire PLC's (LSE:SHP) (Chineham, Basingstoke) Wayne, Pennsylvania, office remains at the top for 2008, followed by Massachusetts where Alexandria Real Estate Equities Incorporated (NYSE:ARE) (Pasadena, California) is in a joint venture to build a 250,000-square-foot facility.
For details, view the entire article by subscribing to Industrial Info's Premium Industry News at http://www.industrialinfo.com/showNews.jsp?newsitemID=135201, or browse other breaking industrial news stories at www.industrialinfo.com.
Related News Articles
Bio Buzz: Life Science Investment Spurs Bipartisanship at its Best at BIO 2008
Pharma-Bio Capital Prognosis: Signs of Life with $12 Billion in Active Grassroot Projects
Construction Begins on $254 Million Cardiovascular Research Institute for UCSF
Contact: Joe Govreau 713-783-5147
SOURCE: Industrial Info Resources